figshare
Browse
Fig 2.tif (413.8 kB)

Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling - Fig 2

Download (413.8 kB)
figure
posted on 2018-01-03, 18:39 authored by Martin Grundy, Claire Seedhouse, Thomas Jones, Liban Elmi, Michael Hall, Adam Graham, Nigel Russell, Monica Pallis

Dynamic BH3 profiling assay: delta priming to (A) BAD-BH3 and (B) MS1-BH3 peptides. Delta priming is measured by cytochrome C release after 4 hour drug treatment and additional incubation with the indicated BH3 peptides (BAD-BH3 at 3 μM, MS1-BH3 at 3 μM, PUMA2A control at 100 μM). Values are corrected for cytochrome C release with peptide only as described in the methods. (Mean+/- SD for n = 3).

History